China Pharma Holdings (CPHI) EBIAT: 2009-2025
Historic EBIAT for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.
- China Pharma Holdings' EBIAT rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.46%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
- Per China Pharma Holdings' latest filing, its EBIAT stood at -$651,482 for Q3 2025, which was down 23.30% from -$528,367 recorded in Q2 2025.
- China Pharma Holdings' EBIAT's 5-year high stood at -$475,976 during Q1 2023, with a 5-year trough of -$1.4 million in Q2 2024.
- Moreover, its 3-year median value for EBIAT was -$800,000 (2025), whereas its average is -$890,457.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 6,418.56% in 2021, then spiked by 63.26% in 2025.
- China Pharma Holdings' EBIAT (Quarterly) stood at -$980,719 in 2021, then fell by 28.90% to -$1.3 million in 2022, then rose by 2.53% to -$1.2 million in 2023, then climbed by 0.63% to -$1.2 million in 2024, then spiked by 41.72% to -$651,482 in 2025.
- Its EBIAT was -$651,482 in Q3 2025, compared to -$528,367 in Q2 2025 and -$800,000 in Q1 2025.